Global Digital Store – Ebooks and Softwares

Tag: Manage

  • New Cabinet portfolio requires time to study: Muhyiddin

    New Cabinet portfolio requires time to study: Muhyiddin

    New Cabinet portfolio requires time to study: Muhyiddin 1

    PUTRAJAYA: Prime Minister Tan Sri Muhyiddin Yassin said today any Cabinet member holding a new portfolio would require time to study the ministry and manage it well.

    Commenting on women’s groups concerns with the Women and Family Ministry’s new appointments, Muhyiddin said he had briefed the newly-minted minister Datuk Seri Rina Mohd Harun about what to do to manage the ministry because she was new at the ministry.

    “But it’s not that she is totally lack of experience. The new portfolio requires everyone to take more time to study,“ he said, adding that he had also told Rina to work closely with her deputy Datuk Siti Zailah Mohd Yusoff.

    According to media reports, women’s rights groups had expressed their concerns over the appointment of Rina and Siti Zailah as the new minister and deputy minister mainly because their track records allegedly do not inspire confidence.

    “What is important is not what her personal view is. What is important is what the government thinks about it and that she or whoever is in the ministry needs to understand,“ Muhyiddin said at a news conference after chairing the Economic Action Council (EAC) meeting here.

    “Bear with us; we will manage it,“ he added. – Bernama

    New Cabinet portfolio requires time to study: Muhyiddin
    Read More
    https://www.thesundaily.my/local/new-cabinet-portfolio-requires-time-to-study-muhyiddin-XC2136505

    Views: 0

  • Why is the UK approach to coronavirus so different to other countries?

    Why is the UK approach to coronavirus so different to other countries?

    The UK’s stance, to try to manage the spread of immunity among people while protecting those most at risk, appears at odds with the World Health Organization’s call for urgent action
    Why is the UK approach to coronavirus so different to other countries?
    Read More
    https://www.newscientist.com/article/2237385-why-is-the-uk-approach-to-coronavirus-so-different-to-other-countries/?utm_campaign=RSS%7CNSNS&utm_source=NSNS&utm_medium=RSS&utm_content=home

    Views: 0

  • TO MANAGE âe¦ OR TO LEAD?

    Have you received a lot of pressure at work from a supervisor to accept a new position that just isn’t fitting with the needs of your family? This story brings to mind some of the distinctions between a Manager and a Leader. Read more here:

    Read More
    http://www.associationofmarketing.org/articles/view.php?article_id=16079

    Views: 0

  • Medical Product Alert N° 1/2020 (English version)

    Medical Product Alert N° 1/2020 (English version)

     

    Falsified antimalarials in West and Central Africa displaying an outdated WHO Essential Drugs Programme logo

    This Medical Product Alert relates to a series of confirmed falsified antimalarials circulating in West and Central Africa. Medicines subject of this alert display a similar logo to the outdated
    WHO Essential Drugs Programme logo.      

    Since 2013, different falsified medicines, all displaying the outdated WHO Essential Drugs Programme logo, have been reported to the WHO Global Surveillance and Monitoring System by various stakeholders. The continued and widespread availability of these falsified medicines highlights a strong need for additional vigilance. WHO previously published two alerts on this issue (No.132 in Oct 2014, and No.131 in March 2014)

    This WHO medical product alert N°1/2020 refers to falsified Quinine Sulphate 300mg presented in six different combinations of batch numbers, expiry and manufacturing dates (see Table 1). The fraudulent use of the outdated WHO Essential Drugs Programme logo may create a false sense of product quality.

    Table 1: List of identified falsified Quinine Sulphate 300mg, subject of WHO Alert N°1/2020

    Medical Product Alert N° 1/2020 (English version) 3

    Recently received results of analysed samples show they do not contain any of the expected active ingredients.

    Quinine sulphate is referenced on the WHO Model List of Essential Medicines, to manage and treat severe malaria. At this stage, no adverse reactions attributed to these falsified products have been reported to WHO.    

    All the above falsified products claim to be manufactured by REMEDICA LTD – Cyprus and to contain 300mg of quinine sulphate. Remedica Ltd has confirmed that:

    • they did not manufacture the above falsified products; and
    • the variable data (batch number and dates) on the above products has never been used by Remedica.

     These falsified medicines display the following common characteristics (please see photographs):

    • grey or white plastic containers which contain 1000 loose circular tablets each;
    • display the outdated WHO Essential Drugs Programme logo;
    • English and French labelling with mistakes and inconsistencies; and
    • discovered at patient level in both regulated and unregulated outlets.

    Product details, photographs and advice to the public are available on the following pages.

    Outdated WHO Essential Drugs Programme logo 

    Medical Product Alert N° 1/2020 (English version) 4

    Photographs of confirmed falsified Quinine Sulphate 300mg tablets subject of
    Medical Product Alert N°1/2020

    1.       Falsified
    Quinine Sulphate Tablets B.P 300mg     identified
    in Chad (Batch 44680)

    Medical Product Alert N° 1/2020 (English version) 5

     

    Medical Product Alert N° 1/2020 (English version) 6

    Medical Product Alert N° 1/2020 (English version) 7Medical Product Alert N° 1/2020 (English version) 8Medical Product Alert N° 1/2020 (English version) 9

    Medical Product Alert N° 1/2020 (English version) 10

     

    WHO requests increased vigilance within the supply chains of countries likely to be affected by these falsified products. Increased vigilance should include hospitals, clinics, health centres, wholesalers, distributors, pharmacies and any other suppliers of medical products.

    If you are in possession of the above products, please do not use. If you have used these falsified products, or if you suffer an adverse event having used these products, please seek immediate advice from a qualified healthcare professional, and ensure they report the incident to your local Ministry of Health/National Medicines Regulatory Authorities/National Pharmacovigilance Centre.

    All medical products must be obtained from authentic and reliable sources. Their authenticity and condition should be carefully checked. Seek advice from a healthcare professional in case of doubt.

    National health authorities are asked to immediately notify WHO if these falsified products are discovered in their country. If you have any information concerning the manufacture, distribution, or supply of these products, please contact rapidalert@who.int . 

    WHO Global Surveillance and Monitoring System

    for Substandard and Falsified Medical Products

    For further information, please visit our website: www.who.int/medicines/regulation/ssffc/en/

     

    Medical Product Alert N° 1/2020 (English version)
    Read More
    https://www.who.int/news-room/detail/09-03-2020-medical-product-alert-n-1-2020-english-version

    Views: 0

  • WHO statement on cases of COVID-19 surpassing 100 000

    WHO statement on cases of COVID-19 surpassing 100 000

    As of today’s reports, the global number of confirmed cases of COVID-19 has surpassed 100 000. As we mark this sombre moment, the World Health Organization (WHO) reminds all countries and communities that the spread of this virus can be significantly slowed or even reversed through the implementation of robust containment and control activities. 

    China and other countries are demonstrating that spread of the virus can be slowed and impact reduced through the use of universally applicable actions, such as working across society to identify people who are sick, bringing them to care, following up on contacts, preparing hospitals and clinics to manage a surge in patients, and training health workers.

    WHO calls on all countries to continue efforts that have been effective in limiting the number of cases and slowing the spread of the virus. 

    Every effort to contain the virus and slow the spread saves lives. These efforts give health systems and all of society much needed time to prepare, and researchers more time to identify effective treatments and develop vaccines. 

    Allowing uncontrolled spread should not be a choice of any government, as it will harm not only the citizens of that country but affect other countries as well. 

    We must stop, contain, control, delay and reduce the impact of this virus at every opportunity. Every person has the capacity to contribute, to protect themselves, to protect others, whether in the home, the community, the health care system, the work place or the transport system. 

    Leaders at all levels and in all walks of life must step forward to bring about this commitment across society. 

    WHO will continue to work with all countries, our partners and expert networks to coordinate the international response, develop guidance, distribute supplies, share knowledge and provide people with the information they need to protect themselves and others.

    WHO statement on cases of COVID-19 surpassing 100 000
    Read More
    https://www.who.int/news-room/detail/07-03-2020-who-statement-on-cases-of-covid-19-surpassing-100-000

    Views: 0

  • Statement on the meeting of the International Health Regulations (2005) Emergency Committee for Ebola virus disease in the Democratic Republic of the Congo on 12 February 2020

    Statement on the meeting of the International Health Regulations (2005) Emergency Committee for Ebola virus disease in the Democratic Republic of the Congo on 12 February 2020

    The meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (IHR) (2005) to review the current Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo (DRC) took place on Wednesday, 12 February 2020, from 14:00 to 16:45 Geneva time (CEST).

    Proceedings of the meeting

    Members and advisors of the Emergency Committee were convened by teleconference.

    The Secretariat welcomed the Committee and thanked them for their support. The meeting was turned over to the Chair, Dr Robert Steffen.

    Dr Steffen also welcomed the Committee and gave the floor back to the Secretariat.

    Representatives of WHO’s legal department and the department of compliance, risk management, and ethics briefed the Committee members on their roles and responsibilities.

    Committee members were reminded of their duty of confidentiality and their responsibility to disclose personal, financial, or professional connections that might be seen to constitute a conflict of interest. Each member who was present was surveyed and no conflicts of interest were judged to be relevant to the meeting.

    The Chair then reviewed the agenda for the meeting and introduced the presenters.

    Presentations were made by representatives of the Ministry of Health of the Democratic Republic of the Congo (DRC), the WHO Secretariat, and the UN Ebola Emergency Response Coordinator.

    The current situation in the DRC was reviewed. As of 10 February 2020, there were a total of 3431 cases, of which 3308 were confirmed and 123 were probable. 2253 persons have died (66%). Between 3 and 9 February 2020, three new confirmed cases were reported in Beni Health Zone, North Kivu. These three cases were already registered as contacts and two were under surveillance at the time of detection. More than 2000 contacts are being followed. There has been an increase in the number of security incidents in recent months.

    Challenges that remain include: strengthening of community acceptance for full commitment to response measures; protection of personnel at strategic health checkpoints; improvement of infection prevention and control practices in health facilities; strengthening of the local health system; and comprehensive treatment and support for patients in recovery.

    The WHO Secretariat gave an overview of the epidemiological situation, which shows an overall encouraging trend in case incidence and geographic spread. It was noted that sustaining this progress depends on the security situation and control of the well-known drivers of transmission, particularly in traditional health facilities, and on continued trust and communication with the community.

    A risk communication and community engagement programme has been developed, as has an EVD survivors programme. It is critical to ensure the long-term sustainability of these two initiatives.   

    The situation in countries neighbouring DRC was reviewed, as was preparedness in nonaffected areas of DRC. An EVD operational readiness standardized approach has been implemented in 9 priority countries. More than 2400 alerts have been investigated, and more than 14,600 health workers have been vaccinated.

    The UN Ebola Emergency Response Coordinator gave a brief report on operational support, focused on security challenges and preparations for any resurgence of disease.

    Context and Discussion

    The Committee noted a great deal of progress in the situation since its last meeting and commended the response, under the leadership of the DRC Ministry of Health and the multisectoral coordination commission established in July 2019. Support provided by WHO, UN agencies, nongovernmental organizations and other partners has also contributed to limiting the spread and impact of this virus in a difficult context. An increase in the number of alerts was attributed to strong and proactive community surveillance.

    Conclusions and Advice

    It was the unanimous view of the Committee that this event still constitutes a public health emergency of international concern (PHEIC) under the IHR (2005).

    The Committee acknowledged the revised risk assessment, which puts the risk now as high at national and regional levels, and low at the global level.

    The Committee was concerned that withdrawing the PHEIC now might have adverse consequences for the response efforts through diminishing focus. Additionally, although the primary concern of the Committee is EVD, there are serious ongoing outbreaks of other diseases, including measles and cholera, in DRC. The country continues to need support to combat infectious diseases as well as to strengthen its health system. Further, there remains an urgent need to maintain international solidarity for the response.

    The Committee noted the ongoing discussions about the interpretation in the text of the IHR (2005) of the terms international and regional spread, and about creating an intermediate level of response between the binary possibilities of PHEIC or no PHEIC, in a way that does not require reopening negotiations on the Regulations. The Committee supports these discussions, as an intermediate level would be as useful for gradually ending a PHEIC and for signaling the potential for one to be declared.

    The Committee provided the following advice to the Director-General for his issuance as revised Temporary Recommendations under the IHR (2005).

    For DRC:

    • Sustain the political commitment and multisectoral coordination approach to the response.
    • Continue to engage and build trust with associations of survivors to facilitate rapid detection of any cases arising from exposure to infected bodily fluids of survivors.
    • Continue to strengthen capacity, implementation, and coordination for community awareness and engagement, including a focus on hotspots, preventing resurgence where cases have declined, and to support survivors in their communities.
    • Further enhance the acceptance of response measures and address access and security issues by engaging influencers and decision makers for all interventions.
    • Strengthen measures to prevent and manage nosocomial infections, including systematic mapping of health facilities, targeting of IPC interventions and sustain support to those facilities through monitoring and supervision, including in private-sector and traditional health facilities.
    • Continue cross-border screening and step up monitoring at checkpoints around hotspots and at main roads.
    • Continue to implement and share real-time full-genome genetic sequencing of all new confirmed cases.
    • Strengthen measures to prevent and manage nosocomial infections, including systematic mapping of health facilities, targeting of IPC interventions and sustain support to those facilities through monitoring and supervision.
    • Strengthen preparedness in non-affected provinces of DRC, and more generally strengthen the health system across the country to respond to concurrent health emergencies.
    • Continue to implement optimal vaccine strategies that have proven maximum impact on curtailing the outbreak, as recommended by WHO’s Strategic Advisory Group of Experts (SAGE).

    For countries at risk:

    • At-risk countries should maintain their work with partners to improve their preparedness for detecting and managing imported or locally acquired cases, including the transparent sharing of detailed information on suspect cases, as required by the International Health Regulations (2005), and sharing laboratory samples of suspect cases for confirmatory testing in accordance with WHO norms and guidance.
    • Countries should continue to map population movements and sociological patterns that can predict risk of disease spread.
    • Risk communications and community engagement, especially at points of entry, should be maintained.

    For all countries:

    • As recommended previously, no country should close its borders or place any restrictions on travel and trade.
    • The Committee does not consider entry screening at airports or other ports of entry outside the region to be necessary.

    The Committee emphasized the importance of continued support by WHO and other national and international partners towards the effective implementation and monitoring of these recommendations.

    Based on this advice, the reports made by the affected State Party, and the currently available information, the Director-General accepted the Committee’s assessment and on 12 February 2020 maintained the Ebola outbreak in the Democratic Republic of the Congo as a Public Health Emergency of International Concern (PHEIC).

    The Director-General endorsed the Committee’s advice and issued them as Temporary Recommendations under IHR (2005) to reduce the international spread of Ebola, effective 12 February 2020. The Director-General thanked the Committee Members and Advisors for their advice and requested their reassessment of this situation within two months or earlier if the situation requires.

    Statement on the meeting of the International Health Regulations (2005) Emergency Committee for Ebola virus disease in the Democratic Republic of the Congo on 12 February 2020
    Read More
    https://www.who.int/news-room/detail/12-02-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-for-ebola-virus-disease-in-the-democratic-republic-of-the-congo-on-12-february-2020

    Views: 0

  • Pregnancy and breastfeeding during an Ebola virus outbreak

    Pregnancy and breastfeeding during an Ebola virus outbreak

    Women who are pregnant or breastfeeding in an Ebola outbreak face similar challenges as other population groups, but they have specific health needs which must be met.

    As the second largest Ebola outbreak in history continues in the Democratic Republic of Congo, WHO has released new clinical guidelines for healthcare providers supporting pregnant or breastfeeding women in the context of Ebola virus disease.

    Improving clinical care and reducing mortality

    92-4-000138-1Clear and coherent guidance is needed to meet the combined needs of women requiring Ebola treatment, pregnancy care and management of complications.

    Information on how to protect breastfeeding children and other members in the community from transmission of the disease is also critical.

    Limited scientific evidence on how to best manage these needs has previously been a challenge for affected countries. In addition, misconceptions that pregnant women have a higher mortality rate than other populations with Ebola may in some contexts have put pregnant women at risk of not receiving standard care.

    WHO’s Guideline on the management of pregnant and breastfeeding women in the context of Ebola virus reviews existing evidence and provides a single set of recommendations on the care continuum for women exposed to, diagnosed with, or recovered from Ebola.

    This will enable healthcare providers, emergency response teams and health policy-makers to improve prevention and treatment measures in an Ebola outbreak.

    Obstetric care at an Ebola Treatment Centre

    Optimal supportive care should be offered to all pregnant women with Ebola. Likewise, they should be offered experimental treatment and vaccination under the same conditions as non-pregnant populations.

    Ebola virus disease does increase the risk of miscarriage and early labour, requiring close clinical management at Ebola treatment centres. It is important to engage both obstetric providers and those trained in Ebola response.

    This dual expertise is also important because early Ebola and pregnancy-related symptoms can overlap. Pregnant women should be prioritised for testing to confirm an Ebola infection.

    Ebola virus can persist in pregnancy related fluids as well as breastmilk. If healthcare providers are not clear on how to manage Ebola infection risk, they may be less willing to provide care. This stigma can be life-threatening for women who experience complications during delivery.

    The new WHO guidelines advise healthcare workers on how to protect themselves while caring for pregnant women with Ebola virus disease. This includes induced labour or surgical procedures, which carry greater risk of transmission in cases of acute infection. Any invasive treatments should be carried out in full personal protective equipment.

    Breastfeeding recommendations in an Ebola outbreak

    WHO recommends that women with suspected or confirmed Ebola immediately stop breastfeeding and are prioritised for diagnostic testing. Any child exposed to Ebola through breast milk should be placed into safe care, closely monitored for symptoms over a 21-day period and fed with an appropriate breast milk substitute.  

    The guidelines strongly recommend that breastfeeding is only restarted following two consecutive negative tests of breast milk, separated by 24 hours.

    A breast milk substitute should be used even if infection is confirmed for both the mother and her child. Exceptions can be made for infants under 6 months of age who are already infected, if breast milk substitutes are not feasible, affordable, sustainable or safe and separation cannot be implemented safely.

    Women’s health and rights in a disease outbreak

    A disease outbreak does not change women’s and adolescent girls’ fundamental human right to sexual and reproductive healthcare, including evidence-based care during pregnancy and childbirth.

    Women need support to make informed reproductive health care choices for themselves and their children. Women living in an Ebola outbreak should have access to all relevant reproductive options, regardless of economic, cultural, racial or religious status, including contraception and safe abortion to the full extent of the law.

    Pregnant and breastfeeding women across affected communities need equitable and respectful care that considers the risks they face and supports the choices they make.

    Accessing the guidelines and further research

    These guidelines are now available online and may be freely downloaded. The executive summary will be available in French.

    WHO will closely monitor new data as it emerges, as there is still a pressing need to prioritise ongoing research related to Ebola virus transmission.

     

     

     

    Pregnancy and breastfeeding during an Ebola virus outbreak
    Read More
    https://www.who.int/news-room/detail/10-02-2020-pregnancy-and-breastfeeding-during-an-ebola-virus-outbreak

    Views: 0

  • WHO and FIND formalize strategic collaboration to drive universal access to essential diagnostics

    Geneva, Switzerland – 10 February 2020 – The World Health Organization (WHO) and the Foundation for Innovative New Diagnostics (FIND) announced today that a memorandum of understanding has been signed by the two organizations to formalize a strategic collaboration that will strengthen diagnosis in resource-poor countries by closing major diagnostic gaps at country level and bolstering disease surveillance that will inform public health initiatives and enhance outbreak preparedness and response.

    “This collaboration is an inspiring development that will take us a long way towards ensuring access to diagnostics to all who need them,” said Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization. “Global health challenges such as the ongoing novel coronavirus (2019-nCoV) outbreak demonstrates that without these essential elements of health systems, we cannot hope to promote health, keep the world safe, and serve the vulnerable. I look forward to working closely with FIND to determine what countries need and to forge a path to deliver these innovations so that no one is left behind.”

    Diagnosis is a driver of patient, financial and health systems impact, and a critical enabler of universal health coverage, but it is also the weakest link in the care cascade. This is especially true in primary healthcare settings in low- and middle-income countries. A unique and unprecedented opportunity exists to expand the role and impact of diagnostics to fully realize their potential to address major health security threats and evolving disease burdens through technological and digital advances.

    FIND has been an active partner with WHO since 2008 and a WHO Collaborating Centre since 2014, acting in the areas of laboratory strengthening and diagnostic technology evaluation. This expanded collaboration will put in place the building blocks necessary to enable transformative change in a move toward a country-led diagnostics alliance. Initial workstreams will focus on demand-driven access to essential diagnostics and the development of national Essential Diagnostics Lists, alongside collection of data that assist the scale up of diagnostics to support low- and middle-income countries on their paths to universal health coverage.

    “Each and every person has the right to a quality, timely diagnosis,” said Catharina Boehme, CEO of FIND. “Comprehensive diagnostic services underpin functional and efficient health systems not only to manage day-to-day healthcare needs, but also to ensure new disease outbreaks can be spotted and contained quickly. Working closely with WHO as part of a country-led alliance, we will strive to ensure that low- and middle-income countries have what they need to develop their own comprehensive, data-driven diagnostic strategies that enable universal health coverage and empower disease surveillance. Our ambition is that all patients, providers and decision-makers have access to the diagnostic solutions needed for optimal health outcomes.”

    The strategic collaboration agreement will initially run for a period of 5 years, until 2025.

    #  #  #

    About FIND

    FIND is a global non-profit organization that drives innovation in the development and delivery of diagnostics to combat major diseases affecting the world’s poorest populations. Our work bridges R&D to access, overcoming scientific barriers to technology development; generating evidence for regulators and policy-makers; addressing market failures; and enabling accelerated uptake and access to diagnostics in low- and middle-income countries (LMICs). Since 2003, we have been instrumental in the development of 24 new diagnostic tools used in 150 LMICs. Over 50 million FIND-supported products have been provided to our target markets since the start of 2015. A WHO Collaborating Centre, we work with more than 200 academic, industry, governmental, and civil society partners worldwide, on over 70 active projects that cross six priority disease areas. FIND is committed to a future in which diagnostics underpin treatment decisions and provide the foundation for disease surveillance, control and prevention. For more information, please visit www.finddx.org

     

    About WHO

    The World Health Organization is the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries and monitoring and assessing health trends. WHO is committed to the enjoyment of the highest attainable standard of health as one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition. WHO’s current global programme of work sets out three interconnected strategic priorities: ensuring healthy lives and well-being for all at all ages; achieving universal health coverage; and addressing health emergencies and promoting healthier populations. These priorities are linked to three ambitious targets, the “triple billion”: one billion more people to benefit from universal health coverage; one billion more people better protected from health emergencies; and one billion more people enjoying better health and well-being.

     

    Read More
    https://www.who.int/news-room/detail/10-02-2020-who-and-find-formalize-strategic-collaboration-to-drive-universal-access-to-essential-diagnostics

    Views: 0

  • A ground penetrating support for self driving navigation in bad weather

    A ground penetrating support for self driving navigation in bad weather

    Consumer confidence in the safety of self-driving cars continues to be a challenge for auto makers planning for an automated driving future, but add to that uneasiness over how well a self-driving car will manage in roads hit by bad weather conditions.

    Views: 0